RE: [NMusers] M3 method with log transformed data

2012-11-22 Thread Mats Karlsson 
Dear Ayappa,

 

This looks fine. However, with NONMEM 7.2 you can also write it as below.
Estimating SIGMA rather than fixing it and estimate a multiplicative THETA
may have speed advantages (and simpler coding for the new methods).

 

$ERROR  
CALLFL=0

IPRED=-3
IPRED=LOG(F)
W=SIGMA(1,1) ;LOG ADDITIVE ERROR
  
LOQ=LOG(0.03);loq is 0.3

DUM=(LOQ-IPRED)/W
CUMD=PHI(DUM)

  IF (BQL.EQ.0) THEN
  IWRES = (DV-IPRED)/W
  F_FLAG=0
 SIMDV = LOG(F)+ERR(1)
 Y=F+W*ERR(1)
ENDIF 
IF (BQL.EQ.1) THEN
  IWRES = 0
  F_FLAG=1
  Y=CUMD
ENDIF

$EST METHOD=COND INTER  LAPLACIAN

$SIGMA 1

 

Best regards,

Mats 

 

Mats Karlsson, PhD

Professor of Pharmacometrics

 

Dept of Pharmaceutical Biosciences

Faculty of Pharmacy

Uppsala University

Box 591

75124 Uppsala

 

Phone: +46 18 4714105

Fax + 46 18 4714003

 

From: owner-nmus...@globomaxnm.com [mailto:owner-nmus...@globomaxnm.com] On
Behalf Of Ayyappa Chaturvedula
Sent: 22 November 2012 00:07
To: nmusers@globomaxnm.com
Subject: [NMusers] M3 method with log transformed data

 

Dear Group,

I want to implement M3 method with log transformed data.  I want to use the
additive error model in log domain and wrote the following code and the runs
are fine.  I want to make sure that I am doing this right.


$ERROR  
CALLFL=0

IPRED=-3
IPRED=LOG(F)
W=THETA(4) ;LOG ADDITIVE ERROR
  
LOQ=LOG(0.03);loq is 0.3

DUM=(LOQ-IPRED)/W
CUMD=PHI(DUM)

  IF (BQL.EQ.0) THEN
  IWRES = (DV-IPRED)/W
  F_FLAG=0
 SIMDV = LOG(F)+W*ERR(1)
 Y=F+W*ERR(1)
ENDIF 
IF (BQL.EQ.1) THEN
  IWRES = 0
  F_FLAG=1
  Y=CUMD
ENDIF

$EST METHOD=COND INTER  LAPLACIAN

$SIGMA 1 FIX

 

Thank you for your help.

 

Regards,

Ayyappa

[NMusers] Next Rosa Impact Webinar: Bench to Bedside Translation of Antibody Drug Conjugates Using a Multiscale Mechanistic PK/PD Model: A Case Study with SGN-35

2012-11-22 Thread Toufigh Gordi 

Bench to Bedside Translation of Antibody Drug Conjugates Using a Multiscale
Mechanistic PK/PD Model: A Case Study with SGN-35


By: Dhavalkumar Shah, PhD


Senior Scientist; Modeling & Simulation, Pharmacokinetics, Dynamics, and
Metabolism; Pfizer
December 11,, 2012
12:00 to 1:00 pm EST


 

 

The presentation will lay out a step by step approach to build and validate
a novel, multiscale, mechanism-based PK/PD model for antibody drug
candidates (ADCs). The model is designed to integrate pre-clinical
biomeasures and PK/PD data to provide pre-clinical-to-clinical translation
of ADC efficacy. The presentation will highlight that it is essential to
understand and characterize the disposition of ADC and payload, at cellular
and physiological levels, to better predict the clinical outcome of ADCs.

 

The purpose of the "Impact" series is to foster the use of M&S activities in
all phases of drug development by illustrating the advantages and enhancing
the applicability of M&S in product discovery, development, and marketing
programs.

The series is intended for drug development project team members from
discovery to phase 4 clinical trials. This includes pharmacologists, ADME
scientists, PK/PD modelers, clinical pharmacologists, clinical development
team members, regulatory affairs specialists, and other interested
professionals.

 

Register for this free webinar at www.rosaandco.com/webinar. After
registering you will receive a confirmation email containing information
about joining the webinar. More information about the webinar series, an
archive of past webinars, and a list of future webinar speakers may be found
at www.rosaandco.com/webinar.

 

Please allow 5-10 minutes for a Java applet to be installed on your computer
prior to joining our webinar series for the first time.

 

Toufigh Gordi

 

 

Toufigh Gordi, PhD

President, PK/PD and Clinical Pharmacology Services

Direct: 408-480-7314

Corp: 408-370-9800

Fax: 408-370-9810

tgo...@rosaandco.com